ArticleACS infectious diseases2018
Targeted Structure-Activity Analysis of Endochin-like Quinolones Reveals Potent Qi and Qo Site Inhibitors of Toxoplasma gondii and Plasmodium falciparum Cytochrome bc
Open access · greenAbstract read
In one paragraph
Article in ACS infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 44 citations in OpenAlex.
- Article
- (3°)- or (4°)-3-Alkylquinolones via Heteroaromatic Claisen Rearrangement.Organic letters · 2026Article
- Quinolones as anti-Toxoplasma agents: a comprehensive scoping review of in vitro and in vivo efficacy.Parasitology research · 2026Article
- Total Synthesis and Antimalarial Studies of Caelestines A-C.ChemMedChem · 2026Article
- Legacy 4(1ACS infectious diseases · 2026Article
- Structure, assembly and inhibition of the Toxoplasma gondii respiratory chain supercomplex.Nature structural & molecular biology · 2025Article
- The Thienopyrimidinone Gamhépathiopine Targets the QACS infectious diseases · 2025Article
- Plant-derived products as anti-leishmanials which target mitochondria: a review.Expert reviews in molecular medicine · 2025Review
- Enhanced Anti-Babesia Efficacy of Buparvaquone and Imidocarb When Combined with ELQ-316 In Vitro Culture ofPharmaceuticals (Basel, Switzerland) · 2025Article
- The Combination of Buparvaquone and ELQ316 Exhibit a Stronger Effect than ELQ316 and Imidocarb AgainstPharmaceutics · 2024Article
- 3-Position Biaryl Endochin-like Quinolones with Enhanced Antimalarial Performance.ACS infectious diseases · 2024Article
- Synthesis of Deuterated Endochin-Like Quinolones.Journal of labelled compounds & radiopharmaceuticals · 2024Article
- Mitochondrial CytochromeTropical medicine and infectious disease · 2024Review
- Antimalarial Dibenzannulated Medium-Ring Keto Lactams.ACS infectious diseases · 2023Article
- A screen of drug-like molecules identifies chemically diverse electron transport chain inhibitors in apicomplexan parasites.PLoS pathogens · 2023Article
- Parasite powerhouse: A review of the Toxoplasma gondii mitochondrion.The Journal of eukaryotic microbiology · 2022Review
- Targeting the cytochrome bcMolecular diversity · 2022Review
- Structure-activity relationships ofExpert opinion on drug discovery · 2022Article
- Siccanin Is a Dual-Target Inhibitor ofPharmaceuticals (Basel, Switzerland) · 2022Article
- Dual inhibition of theFrontiers in veterinary science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Erin V McConnellVA Portland Health Care System Research and Development Service , 3710 SW US Veterans Hospital Road , Portland , Oregon 97239 , United States.
Igor BruzualVA Portland Health Care System Research and Development Service , 3710 SW US Veterans Hospital Road , Portland , Oregon 97239 , United States.
Sovitj PouVA Portland Health Care System Research and Development Service , 3710 SW US Veterans Hospital Road , Portland , Oregon 97239 , United States.
Rolf WinterVA Portland Health Care System Research and Development Service , 3710 SW US Veterans Hospital Road , Portland , Oregon 97239 , United States.
Rozalia A DodeanVA Portland Health Care System Research and Development Service , 3710 SW US Veterans Hospital Road , Portland , Oregon 97239 , United States.
Martin J SmilksteinVA Portland Health Care System Research and Development Service , 3710 SW US Veterans Hospital Road , Portland , Oregon 97239 , United States.
Alina KrollenbrockOregon Health & Science University Department of Physiology and Pharmacology , 3181 SW Sam Jackson Park Road , Portland , Oregon 97239 , United States.
Aaron NilsenVA Portland Health Care System Research and Development Service , 3710 SW US Veterans Hospital Road , Portland , Oregon 97239 , United States.
Lev N ZakharovDepartment of Chemistry , University of Oregon , 1585 E 13th Avenue , Eugene , Oregon 97403 , United States.
Michael K RiscoeVA Portland Health Care System Research and Development Service , 3710 SW US Veterans Hospital Road , Portland , Oregon 97239 , United States.
J Stone DoggettVA Portland Health Care System Research and Development Service , 3710 SW US Veterans Hospital Road , Portland , Oregon 97239 , United States.ORCID 0000-0002-6098-1520
VA Portland Health Care System · USOregon Health & Science University · USUniversity of Oregon · US
Funding
Optimizing ELQs for Treatment and Prevention of MalariaR01AI100569 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Michael Kevin RISCOE · 2014 to 2026
$8.0MINTERACTIONS AT THE MICROBE/HOST INTERFACET32AI007472 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI LANDFEAR, SCOTT M · 1995 to 2019
$6.7MDevelopment of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQsR01AI141412 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI RISCOE, MICHAEL KEVIN · 2019 to 2022
$3.2MDevelopment of endochin-like quinolones for babesiosis therapyR01AI123321 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2017 to 2020
$2.7MDevelopment of the potent anti-malarial and anti-Toxoplasma drug, ELQ-316IK2BX002440 · VA · PORTLAND VA MEDICAL CENTER · PI DOGGETT, JOSEPH STONE · 2014 to 2018
–ShEEP Request for Parkin-Elmer Spectrum Series Bio-imaging DeviceIS1BX003568 · VA · PORTLAND VA MEDICAL CENTER · PI RISCOE, MICHAEL KEVIN · 2016 to 2016
–Pharmachin Optimization and TestingI01BX003312 · VA · PORTLAND VA MEDICAL CENTER · PI RISCOE, MICHAEL KEVIN · 2016 to 2025
–Optimizing Pharmachins for Treatment and Prevention of Drug Resistant MalariaI01BX001421 · VA · PORTLAND VA MEDICAL CENTER · PI RISCOE, MICHAEL KEVIN · 2012 to 2015
–BLRD VA I01 BX001421BLRD VA I01 BX003312BLRD VA IK2 BX002440BLRD VA IK6 BX004857BLRD VA IS1 BX003568NIAID NIH HHS R01 AI100569NIAID NIH HHS R01 AI123321NIAID NIH HHS R01 AI141412NIAID NIH HHS T32 AI007472
Abstract
Cytochrome bc
Indexed as
AnimalsAntiprotozoal AgentsCells, CulturedDrug DiscoveryDrug ResistanceElectron Transport Complex IIIHumansMalaria, FalciparumMiceMolecular StructurePhenyl EthersPlasmodium falciparumQuinolonesStructure-Activity RelationshipToxoplasmaToxoplasmosisAntiprotozoal AgentsElectron Transport Complex IIIELQ-400Phenyl EthersQuinolonescytochrome bc1malariaPlasmodium falciparumtherapeuticsToxoplasma gondiitoxoplasmosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.